Skip to main content
. 2018 May;15(5):515–517. doi: 10.1513/AnnalsATS.201711-848PS

Figure 1.

Figure 1.

The bullets indicate the current status of key issues related to intrapleural fibrinolytic therapy and are predicated upon the authors’ synthesis of the literature. ADA = anti-drug antibodies; CPE = complicated parapneumonic pleural effusions; EMP = empyema; IPFT = intrapleural fibrinolytic therapy.